Recent

% | $
Quotes you view appear here for quick access.

Threshold Pharmaceuticals Inc. Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • tredleon tredleon Apr 11, 2007 1:14 PM Flag

    Erbitux fails...

    I always believed there was a better chance of success in the current P2 trial (in combination with Gemzar) than the recently failed P3 trial (end-stage for those who failed first-line Gemzar therapy), but bought a small position in the fall of last year anyway. I'm still trying to decide whether I want to add to my position - the preliminary P2 results are showing good "objective response", but survival is the only thing that matters, and there may not be much of a connection between shrinking/halting the growth of tumors and extending patients lives? But I keep thinking that the bar is so low (even a 2-3 month impact on survival would be significant) that Glufo just might pull it off. This one is definitely a crapshoot, but if it helps in pancreatic cancer, I think it will most likely be successful as a combination agent in other solid tumor treatments, so there is good upside potential.

 
THLD
0.4795+0.0321(+7.17%)May 27 4:00 PMEDT